Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q99986

UPID:
VRK1_HUMAN

ALTERNATIVE NAMES:
Vaccinia-related kinase 1

ALTERNATIVE UPACC:
Q99986; Q3SYL2

BACKGROUND:
The Serine/threonine-protein kinase VRK1, known alternatively as Vaccinia-related kinase 1, is a crucial enzyme in cell cycle progression, transcription regulation, and nuclear architecture. It phosphorylates several key proteins including p53/TP53, influencing their activity and stability. VRK1's role extends to DNA damage response, where it modifies KAT5, facilitating its histone acetyltransferase function, and impacts Golgi structure during cell division.

THERAPEUTIC SIGNIFICANCE:
Linked to the genetic disorder Pontocerebellar hypoplasia 1A, VRK1's genetic variants underscore its clinical importance. The disorder's manifestation, including cerebellar and brainstem abnormalities, underscores the therapeutic potential in targeting VRK1 for intervention. Exploring VRK1's functions and interactions offers a promising avenue for developing novel treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.